FDA Clears Screening Algorithm to Assess for Interstitial Lung Disease
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.
Tag: interstitial lung disease
All
Latest
FDA Clears Screening Algorithm to Assess for Interstitial Lung Disease
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.
Read More
Antidepressant Often Prescribed Off-label Fails to Ease Breathlessness in Respiratory Patients
Patients receiving the drug also had slightly more side effects and needed more care from hospitals and family members.
Read More
Investigational Antibody Treatment Shows Promise for Fibrotic Lung Diseases
Preclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Read More
Could Arthritis Drugs Alleviate Long COVID Lung Symptoms?
Researchers have identified a potential treatment for the respiratory symptoms of long COVID by discovering an unknown cause of the condition within the lungs.
Read More
Congress Introduces SOAR Act to Improve Supplemental Oxygen Access
The Supplemental Oxygen Access Reform Act of 2024, designed to ease access to supplemental oxygen for Medicare beneficiaries, was introduced in the US House of Representatives by a bipartisan group of members of Congress.
Read More
Model Created to Decode ABCA3 Mutation’s Role in Childhood Lung Disease
Researchers demonstrate how they can now study the most common genetic cause of pediatric interstitial lung disease using stem cells generated from each patient.
Read More
FDA Clears AI-Powered Idiopathic Pulmonary Fibrosis Diagnostic
According to Imvaria, the device’s manufacturer, the clearance signifies the first FDA authorization of a diagnostic tool of any type in lung fibrosis.
Read More
Omega-3 Fatty Acids May Slow Pulmonary Fibrosis
Higher levels of omega-3 fatty acids were associated with better lung function and longer transplant-free survival in patients with pulmonary fibrosis, a new study finds.
Read More
New Guidance for Treating Systemic Sclerosis-associated ILD
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
Read More
Guidance for Diagnosis and Treatment of Pulmonary Hypertension Related to ILD
The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
Read More
CHEST Awards Grants to Accelerate ILD Diagnosis
CHEST announced the recipients of quality improvement grants aimed at shortening the time to diagnosis for interstitial lung disease.
Read More
ILD Diagnostic Validated in Two New Studies Presented at CHEST
Two studies presented at CHEST 2023 validated the effectiveness of the Envisia Genomic Classifier in improving the detection of interstitial lung disease.
Read More
7 New Sites Join PFF Care Center Network
The Pulmonary Fibrosis Foundation announced that seven medical centers have joined the PFF Care Center Network as clinical associate members, a new membership option.
Read More
Cleveland Clinic Pulmonologist Takes Helm at Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation announced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, effective Sept 15.
Read More
Pulmonary Rehabilitation Gets ‘Strong’ Recommendation in New ATS Guideline
The latest guideline from the American Thoracic Society reaffirms benefits for patients with COPD as well as pulmonary hypertension and interstitial lung disease.
Read More
FDA Greenlights Phase 2 Trial of OATD-01 for Pulmonary Sarcoidosis
The phase 2 clinical trial is expected to be a multi-center, randomized, double-blind, placebo-controlled study assessing the drug’s safety and effectiveness in treating approximately 90 pulmonary sarcoidosis patients.
Read More
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read More
Toolkit to Support Clinicians in Quicker Diagnosis of ILDs
The new toolkit, shared on Rare Disease Day, aims to help clinicians shorten the time to diagnosis for pulmonary fibrosis and other interstitial lung diseases.
Read More
Interstitial Lung Disease in Hospitalized COVID Patients
Approximately 11% of hospitalized COVID-19 patients had fibrotic patterning after recovery from acute illness, according to a new study from Imperial College London researchers published in AJRCCM.
Read More
Interstitial Lung Disease Common After COVID-19
Researchers estimated that up to 11% of hospitalized COVID-19 patients had interstitial lung disease after recovery from COVID.
Read More
Pulmonary Fibrosis Research on Access, Quality of Care
Important research results from five studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease (ILD) are being presented at ATS 2022.
Read More
Reducing Delays in Interstitial Lung Disease Diagnosis
Three Lakes Foundation and the American College of Chest Physicians (Chest) recently announced...
Read MoreExperimental Therapy Could Help People with Lung Disease
Scientists at the University of Texas MD Anderson Cancer Center have developed a drug to treat the uncontrolled secretion of mucins in the airways.
Read More
Boehringer Pulmonary Fibrosis Drug Gets FDA Breakthrough Status
Boehringer Ingelheim’s BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.
Read More